Lastly, in Ad-TK + Ad-flt3L-treated mice, the accumulation of antigen-bearing activated B cells within tumor-draining lymph nodes (TDLNs) along with evidence that the activated B cells were capable of stimulating CD8+ T cell proliferation in vitro were strong clues that B cells can cross-prime CD8+ T cells against glioma antigens and thereby orchestrate glioma regression (160). The gene discussed is CD8A; the disease is glioma.